[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360729-105":59,"doc-detail-360729-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","plasma-protein-analysis-for-biomarker-discovery-in-lung-cancer-treated-with-atezolizumab-combination-therapy-in-j-tail-2","Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2","","J-TAIL-2 evaluated atezolizumab, an anti–PD-L1 agent, combined with chemotherapy in Japanese practice for non-small cell lung cancer and extensive-stage small cell lung cancer, showing outcomes comparable with Phase 3 trials. While PD-L1 may predict benefit in certain contexts, additional minimally invasive, blood-based biomarkers are required. This exploratory biomarker study analyzed 359 patients and assessed ~560 cancer- or immune-related proteins in plasma using Proximity Extension Assay at three timepoints. Protein associations were linked to clinical outcomes, identifying regimen- and subgroup-dependent immune signals relevant to efficacy and immune-related adverse events.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasma-protein-analysis-for-biomarker-discovery-in-lung-cancer-treated-with-atezolizumab-combination-therapy-in-j-tail-2/360729/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasma-protein-analysis-for-biomarker-discovery-in-lung-cancer-treated-with-atezolizumab-combination-therapy-in-j-tail-2/360729.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What biomarkers were measured in the J-TAIL-2 exploratory study?","Question",{"text":113,"@type":114},"The study evaluated approximately 560 cancer- or immune-related proteins in blood plasma. Measurements were performed using the Proximity Extension Assay at baseline, before the second atezolizumab dose, and at immune-related adverse event onset.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which protein markers were associated with shorter progression-free survival?",{"text":118,"@type":114},"IL-6, MUC-16, and KRT-19 were associated with shorter progression-free survival across multiple regimens.",{"name":120,"@type":111,"acceptedAnswer":121},"How did protein findings relate to immune-related adverse events and treatment response?",{"text":122,"@type":114},"Baseline immune stimulation proteins were linked to immune-related adverse events across regimens. Immune activation markers, including Granzyme A and B, were elevated in responders receiving atezolizumab plus CnP and atezolizumab plus bevacizumab-carboplatin-paclitaxel.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360729,1790207604,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nDrug Discovery and Delivery  \nPlasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2  \nYasushi Goto1  | Makoto Nishio2  | Kadoaki Ohashi3  | Atsushi Osoegawa4 | Eiki Kikuchi5  | Hideharu Kimura6 | Junichi Shimizu7 | Eisaku Miyauchi8  | Hiroshige Yoshioka9,10  | Ichiro Yoshino11,12 | Toshihiro Misumi13 |  \nYasutaka Watanabe14 | Nobuyuki Katakami15  | Akira Kisohara16 | Masafumi Yamaguchi17 | Hirotaka Kuroki18 | Masamichi Sugimoto18 | Hisao Ashimura18 | Misa Tanaka18 | Akihiko Gemma19   \n1Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan | 2Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan | 3Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan | 4Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Japan | 5Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan | 6Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan | 7Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan | 8Department of Respiratory Medicine, Tohoku University Hospital, Sendai,  \nJapan | 9Department of Thoracic Oncology, Kansai Medical University, Hirakata, Japan | 10Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan | 11Department of Thoracic Surgery, International University of Health and Welfare Narita Hospital, Narita, Japan | 12Department of General Thoracic Surgery, Chiba University Hospital, Chiba, Japan | 13Department of Data Science, National Cancer Center Hospital East, Kashiwa, Japan | 14Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan | 15Department of Pulmonary Medicine and Medical Oncology, Takarazuka City Hospital, Takarazuka, Japan | 16Department of Respiratory Medicine, Kasukabe Medical Center, Kasukabe, Japan | 17Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan | 18Chugai Pharmaceutical Co. , Ltd., Tokyo, Japan | 19Nippon Medical School, Tokyo, Japan  \nCorrespondence: Akihiko Gemma ([agemma@nms.ac.jp](agemma@nms.ac.jp))  \nReceived: 6 October 2025 | Revised: 11 March 2026 | Accepted: 17 March 2026  \nKeywords: atezolizumab | biomarker | non-small cell lung cancer | plasma protein | small cell lung cancer  \nABSTRACT  \nJ-TAIL-2 evaluated the efficacy and safety of atezolizumab, an anti–programmed death-ligand 1 (PD-L1), plus chemotherapy in patients with non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) in Japanese clinical practice, demonstrating comparable outcomes to those in the corresponding Phase 3 trials. Although PD-L1 expression is predictive of atezolizumab efficacy in some settings, additional minimally invasive, blood-based biomarkers are needed. This exploratory biomarker study included 359 J-TAIL-2 patients. The NSCLC cohort received atezolizumab combined with carboplatin and nab-paclitaxel (CnP, n = 42), cisplatin/carboplatin and pemetrexed (n = 72), or bevacizumab plus carboplatin and paclitaxel (bev + CP, n = 135) . The ES-SCLC cohort received atezolizumab plus carboplatin and etoposide (n = 100) . Approximately 560 cancer- or immune-related proteins were evaluated using the Proximity Extension Assay from blood plasma collected at three timepoints: baseline, before the second atezolizumab dose, and at the onset of immune-related  \n\n| Abbreviations: AE, adverse event; Atezo + bev + CP, atezolizumab plus bevacizumab plus carboplatin and paclitaxel; Atezo + CE, atezolizumab plus carboplatin and etoposide; Atezo + CnP, atezolizumab plus carboplatin and nab-paclitaxel; Atezo + PP, atezolizumab plus carboplatin or cisplatin plus pemetrexed; CI, confidence interval; CnP, carboplatin and nab-paclitaxel; ECOG PS, Easte","cbCaiaB6x5hFGQvi","https://ap.wps.com/l/cbCaiaB6x5hFGQvi","pdf",747883,13,"English","# Introduction\n## Plasma protein biomarker analysis workflow\n## Protein associations with clinical outcomes and irAEs\n## Trial design and patient cohorts","[{\"question\":\"What biomarkers were measured in the J-TAIL-2 exploratory study?\",\"answer\":\"The study evaluated approximately 560 cancer- or immune-related proteins in blood plasma. Measurements were performed using the Proximity Extension Assay at baseline, before the second atezolizumab dose, and at immune-related adverse event onset.\"},{\"question\":\"Which protein markers were associated with shorter progression-free survival?\",\"answer\":\"IL-6, MUC-16, and KRT-19 were associated with shorter progression-free survival across multiple regimens.\"},{\"question\":\"How did protein findings relate to immune-related adverse events and treatment response?\",\"answer\":\"Baseline immune stimulation proteins were linked to immune-related adverse events across regimens. Immune activation markers, including Granzyme A and B, were elevated in responders receiving atezolizumab plus CnP and atezolizumab plus bevacizumab-carboplatin-paclitaxel.\"}]","Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2 | PDF",1790141356,33]